Back to Search
LAURENCE GORE, PH.D.
PH.D.
Clinical Psychologist
NPI: 1720129794IndividualAccepts Medicare
Specialties, Licenses & Credentials
Clinical PsychologistPrimary
Psychologist — Clinical
Code: 103TC0700X
P.7116(OH)PSY17037(CA)
CMS Specialties
PrimaryCLINICAL PSYCHOLOGIST
Education
OTHER
Class of 2021
Research & Publications (20)
The National Report Card on the State of Emergency Medicine: evaluating the emergency care environment state by state 2009 edition.
PMID 19111195·Ann Emerg Med·2009
8-other
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
PMID 18985740·Pediatr Blood Cancer·2009
2-rct
A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
PMID 18509645·Cancer Chemother Pharmacol·2009
8-other
Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors.
PMID 18985717·Pediatr Blood Cancer·2009
8-other
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
PMID 19652058·J Clin Oncol·2009
3-trial
PARP1 expression in pediatric central nervous system tumors.
PMID 19533660·Pediatr Blood Cancer·2009
8-other
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
PMID 18618082·Invest New Drugs·2009
3-trial
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
PMID 18043132·Anticancer Drugs·2008
3-trial
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
PMID 18058098·Cancer Chemother Pharmacol·2008
3-trial
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
PMID 19074845·Mol Cancer Ther·2008
3-trial
Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.
PMID 18928662·Curr Oncol Rep·2008
6-review
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
PMID 18579665·Clin Cancer Res·2008
3-trial
Oncogenic and angiogenic growth factors accumulate during routine storage of apheresis platelet concentrates.
PMID 18559616·Clin Cancer Res·2008
8-other
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
PMID 18390968·J Clin Oncol·2008
3-trial
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
PMID 18320191·Cancer Chemother Pharmacol·2008
3-trial
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
PMID 17363533·Clin Cancer Res·2007
3-trial
Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect?
PMID 18086346·Semin Oncol·2007
5-case
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.
PMID 17693653·Ann Oncol·2007
3-trial
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
PMID 16609952·Pediatr Blood Cancer·2007
8-other
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.
PMID 17000682·Clin Cancer Res·2006
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 455 N. SHAWNEE LN
CHILLICOTHE, OH 45601 - Phone
- (740) 779-4888
Quick Facts
- NPI
- 1720129794
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 5
- Publications
- 20
Are you this provider?
Claim Your Profile